Lantheus Medical Imaging's parent company, Lantheus Holdings, has announced its first commercial shipment of xenon-133 gas using unprocessed radiochemical supplied by the Institute for Radioelements (IRE).
IRE will supplement and eventually replace the firm's current supply of the gas when the National Research Universal (NRU) reactor in Canada stops regularly providing medical isotopes to the marketplace in October 2016, Lantheus said.
